65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details
臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04925375 (ClinicalTrials.gov) | July 14, 2021 | 11/5/2021 | Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease | Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease | Interstitial Lung Disease;Common Variable Immunodeficiency | Drug: Abatacept;Other: Placebo | Children's Hospital Medical Center, Cincinnati | Bristol-Myers Squibb | Recruiting | 4 Years | N/A | All | 60 | Phase 2 | United States |
| 2 | EUCTR2015-002491-24-DE (EUCTR) | 11/05/2016 | 30/03/2016 | Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease | Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease - SAIL | CVID patients confirmed according to ESID/PAGID criteria or related disorders which fulfill the diagnostic criteria for CVID and interstitial lung disease or granuloma diagnosed by chest CT positive for nodules, lines or ground-glass signs MedDRA version: 18.1;Level: PT;Classification code 10022611;Term: Interstitial lung disease;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 18.1;Classification code 10021449;Term: Immunodeficiency common variable;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: ORENCIA® 125 mg solution for injection in pre-filled syringe Product Name: Abatacept Product Code: BMS-188667 | Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Germany | ||
| 3 | NCT01917708 (ClinicalTrials.gov) | January 2014 | 24/7/2013 | Bone Marrow Transplant With Abatacept for Non-Malignant Diseases | Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Diseases | Hurler Syndrome;Fanconi Anemia;Glanzmann Thrombasthenia;Wiskott-Aldrich Syndrome;Chronic Granulomatous Disease;Severe Congenital Neutropenia;Leukocyte Adhesion Deficiency;Shwachman-Diamond Syndrome;Diamond-Blackfan Anemia;Dyskeratosis-congenita;Chediak-Higashi Syndrome;Severe Aplastic Anemia;Thalassemia Major;Hemophagocytic Lymphohistiocytosis;Sickle Cell Disease | Drug: Abatacept | Emory University | NULL | Completed | N/A | 21 Years | All | 10 | Phase 1 | United States |
| 4 | EUCTR2008-003368-21-IT (EUCTR) | 04/06/2008 | 06/02/2009 | Pilot trial of CTLA4-Ig (Abatacept) in a child affected by a severe congenital autoimmune syndrome (IPEX) - Trial of Abatacept in IPEX syndrome | Pilot trial of CTLA4-Ig (Abatacept) in a child affected by a severe congenital autoimmune syndrome (IPEX) - Trial of Abatacept in IPEX syndrome | For patients with a stabilized clinical condition, not recovered in care units for acute problems. MedDRA version: 9.1;Level: HLGT;Classification code 10003816 MedDRA version: 9.1;Level: HLT;Classification code 10027657 | Trade Name: ORENCIA INN or Proposed INN: ABATACEPT | ISTITUTO PER L`INFANZIA BURLO GAROFOLO | NULL | Not Recruiting | Female: no Male: yes | Italy |